The 2026 approval of a second tau PET tracer gives primary-care patients a more sensitive way to confirm tau tangles during an Alzheimer's evaluation. It does not replace blood tests or guarantee coverage, so cost checks and follow-up questions still shape the workup.
Tau imaging means a brain PET scan that shows tau tangles, twisted fibers that build up inside brain cells in Alzheimer's disease. Lantheus announced on Aug. 14, 2026 that FDA approved TAUKLARIFY for brain PET in adults with cognitive impairment being evaluated for Alzheimer's to identify that pathology Lantheus approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the new tau scan add?
- Where do blood tests fit before PET?
- What affects access and cost?
- What should you ask your primary-care doctor?
What does the new tau scan add?
Tauklarify uses florquinitau F 18 to make tau tangles visible on PET. It joins Eli Lilly's flortaucipir as only the second FDA-approved tau tracer. AlzForum reported it as more sensitive, including for tangles limited to the medial temporal lobe AlzForum research report. That sensitivity matters early, when memory symptoms are new and tangles may sit in a small memory area.
A clearer medial temporal signal can help specialists place tau findings alongside memory testing and other results. The use remains narrow. Pharmacy Times notes safety and effectiveness are not established for non-Alzheimer's tauopathies or outside evaluation of cognitively impaired adults for Alzheimer's disease. Primary-care patients without objective impairment do not fit that use.
Where do blood tests fit before PET?
Blood tests usually come first in primary care because they are simpler than PET. LTC News reported that FDA has cleared four blood biomarker tests since May 2025, most recently Roche Elecsys pTau217 on Aug. 24, 2026 as the first single-biomarker test validated to both rule in and rule out amyloid in primary and specialty care LTC News test summary.
The Alzheimer's Association guideline covers blood biomarkers only for objective impairment seen in specialty care. It sets high accuracy bars for triage use needing PET or spinal-fluid confirmation, and higher bars for use as a substitute. For patients, this means a blood result often starts the talk rather than ends it. A primary-care doctor may refer for specialty review, repeat testing, or PET when the result and symptoms point toward Alzheimer's.
What affects access and cost?
Access depends on referral rules and local coverage more than FDA approval alone. PET coverage varies by payer and, for amyloid PET, CMS left decisions to local contractors after retiring national coverage rules in 2023. Medicare Part B in 2026 generally requires medical necessity, with a deductible then coinsurance, according to Humana Humana Medicare PET guide.
Humana lists a $283 deductible then 20 percent coinsurance for covered PET scans. Patients should confirm whether a planned tau scan has a local coverage path and what their share would be. Without insurance, HelpDementia places an amyloid PET scan at about $3,000. That figure does not set the price for tau PET, but it shows why families ask early about authorization and approved centers.
What should you ask your primary-care doctor?
Bring symptoms, medicines, and what you want the result to change. Ask whether objective impairment is documented and whether a blood test or specialist visit should come before PET.
Ask how tau results would affect diagnosis, care plans, or referral for anti-amyloid therapy and MRI monitoring. Use these checks at the visit: Take written notes on the answers and keep the test order, center name, and authorization number together. That record helps if coverage needs an appeal or a second review.
- Do I need a referral and prior authorization for PET?
- Which imaging center is approved for this tracer?
- Will I need confirmatory PET or spinal-fluid testing after blood work?
- How will results affect treatment eligibility and follow-up scans?
- What medical-necessity notes will support coverage?
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Access, Cost, and Follow-Up Questions for Primary Care Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Access, Cost, and Follow-Up Questions for Primary Care Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Access, Cost, and Follow-Up Questions for Primary Care Patients
